S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NASDAQ:LMAT

LeMaitre Vascular Stock Forecast, Price & News

$47.40
+0.61 (+1.30%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.38
$49.14
50-Day Range
$46.79
$59.05
52-Week Range
$34.23
$64.50
Volume
107,665 shs
Average Volume
124,328 shs
Market Capitalization
$1.04 billion
P/E Ratio
35.91
Dividend Yield
0.94%
Beta
1.3
30 days | 90 days | 365 days | Advanced Chart
Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.


LeMaitre Vascular logo

About LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMAT
Employees
395
Year Founded
1983

Sales & Book Value

Annual Sales
$129.37 million
Cash Flow
$1.42 per share
Book Value
$8.48 per share

Profitability

Net Income
$21.22 million
Pretax Margin
23.16%

Debt

Price-To-Earnings

Miscellaneous

Free Float
18,759,000
Market Cap
$1.04 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/28/2021
Ex-Dividend
11/18/2021
Today
12/01/2021
Dividend Payable
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

3.23 out of 5 stars

Medical Sector

12th out of 1,392 stocks

Surgical & Medical Instruments Industry

1st out of 127 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 3.3Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

Is LeMaitre Vascular a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LeMaitre Vascular stock.
View analyst ratings for LeMaitre Vascular
or view top-rated stocks.

How has LeMaitre Vascular's stock price been impacted by COVID-19?

LeMaitre Vascular's stock was trading at $26.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LMAT shares have increased by 81.6% and is now trading at $47.40.
View which stocks have been most impacted by COVID-19
.

Are investors shorting LeMaitre Vascular?

LeMaitre Vascular saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 1,000,000 shares, a decline of 23.1% from the September 30th total of 1,300,000 shares. Based on an average trading volume of 104,300 shares, the short-interest ratio is presently 9.6 days. Approximately 5.3% of the shares of the company are sold short.
View LeMaitre Vascular's Short Interest
.

When is LeMaitre Vascular's next earnings date?

LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for LeMaitre Vascular
.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) posted its quarterly earnings results on Thursday, October, 28th. The medical instruments supplier reported $0.30 EPS for the quarter, missing the consensus estimate of $0.33 by $0.03. The medical instruments supplier earned $38.37 million during the quarter, compared to analysts' expectations of $39.05 million. LeMaitre Vascular had a trailing twelve-month return on equity of 14.15% and a net margin of 18.21%. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.37 earnings per share.
View LeMaitre Vascular's earnings history
.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Tuesday, October 26th. Shareholders of record on Friday, November 19th will be given a dividend of $0.11 per share on Thursday, December 2nd. This represents a $0.44 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend is Thursday, November 18th.
View LeMaitre Vascular's dividend history
.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular pays an annual dividend of $0.44 per share and currently has a dividend yield of 0.94%. LeMaitre Vascular has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of LeMaitre Vascular is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 30.56% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.
View LeMaitre Vascular's dividend history.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular issued an update on its fourth quarter 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share guidance of $0.290-$0.340 for the period, compared to the Thomson Reuters consensus estimate of $0.340. The company issued revenue guidance of $39 million-$41 million, compared to the consensus revenue estimate of $40.18 million.

What price target have analysts set for LMAT?

5 brokerages have issued 1 year price objectives for LeMaitre Vascular's shares. Their forecasts range from $58.00 to $70.00. On average, they anticipate LeMaitre Vascular's share price to reach $64.25 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts' price targets for LeMaitre Vascular
or view top-rated stocks among Wall Street analysts.

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the following people:

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular CEO George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among LeMaitre Vascular's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include (CGC), AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and salesforce.com (CRM).

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.27%), Conestoga Capital Advisors LLC (8.52%), Copeland Capital Management LLC (4.45%), Geneva Capital Management LLC (4.14%), Dimensional Fund Advisors LP (3.12%) and Geode Capital Management LLC (1.54%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends for LeMaitre Vascular
.

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including Tygh Capital Management Inc., Two Sigma Investments LP, Bridge City Capital LLC, Dimensional Fund Advisors LP, Scout Investments Inc., Geneva Capital Management LLC, Janus Henderson Group PLC, and Krane Funds Advisors LLC. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, John A Roush, Lawrence J Jasinski, and Trent G Kamke.
View insider buying and selling activity for LeMaitre Vascular
or view top insider-selling stocks.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Pura Vida Investments LLC, Assenagon Asset Management S.A., Renaissance Technologies LLC, Copeland Capital Management LLC, Citadel Advisors LLC, Russell Investments Group Ltd., and Morgan Stanley.
View insider buying and selling activity for LeMaitre Vascular
or or view top insider-buying stocks.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $47.40.

How much money does LeMaitre Vascular make?

LeMaitre Vascular has a market capitalization of $1.04 billion and generates $129.37 million in revenue each year. The medical instruments supplier earns $21.22 million in net income (profit) each year or $1.32 on an earnings per share basis.

How many employees does LeMaitre Vascular have?

LeMaitre Vascular employs 395 workers across the globe.

Does LeMaitre Vascular have any subsidiaries?

The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.

When was LeMaitre Vascular founded?

LeMaitre Vascular was founded in 1983.

What is LeMaitre Vascular's official website?

The official website for LeMaitre Vascular is www.lemaitre.com.

Where are LeMaitre Vascular's headquarters?

LeMaitre Vascular is headquartered at 63 SECOND AVENUE, BURLINGTON MA, 01803.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.